BDO has appointed Martin Gouldstone as a director within the corporate finance pharmaceutical team based in Baker Street, London.
He joins with a wealth of experience in the sector, having worked in the biopharma industry for more than 20 years.
Gouldstone joins from the biopharmaceutical development and commercial outsourcing consultancy Quintiles, where he worked as a senior director in the corporate development department and established its product strategy practice within consulting. As part of this role, Gouldstone was responsible for M&A activities across Europe, the Middle East &Africa and acted as the lead on several large client accounts for the firm.
Prior to joining Quintiles, Gouldstone was the business development and licensing lead in several EU and US biotech companies.
BDO closed 214 deals in 2013, following only three of the Big Four accountancy firms and investment bank Goldman Sachs.
Jamie Austin, M&A partner at BDO, says: “Martin joins at an exciting time for BDO as we bolster our pharmaceuticals credentials, a sector of growing importance to us in the UK. His appointment adds to the excellent international franchise that BDO already has in the areas of life sciences and healthcare. Martin’s expansive M&A experience within the sector will complement our existing corporate finance offering, add value to our Management Consulting service and reinforces BDO’s commitment to clear, sector focused, high quality advice.”
Gouldstone says: “I believe that there is a fantastic opportunity to grow and develop BDO’s position as a trusted adviser in the pharmaceuticals sector, helping our clients to realise their inorganic growth strategies at a time of unprecedented challenge and opportunity in the global pharmaceuticals environment.”
